Under the proposal the group is drafting, PhRMA members would limit increases for the prices of drugs purchased by Medicare to a measure of consumer inflation.
The proposal is aimed at persuading CMS to abandon a plan to create an “international pricing index” and use it as a benchmark to decide how much Medicare would pay for drugs covered by Part B, which covers physician visits for seniors and drugs prescribed to them during their visits.
PhRMA hasn’t decided whether the proposal would be limited to Part B or if it will also include drugs dispensed at retail pharmacies and purchased by Part D.
The PhRMA board is likely to endorse the proposal, according to the pharma executives that spoke with BioCentry, who asked not to be named.
More articles on pharmacy:
Cancer therapy prices prevent access to treatment, WHO says
Despite controversies, J&J ranks among Fortune’s most-admired companies
Bristol-Myers swings to $1.2B profit in Q4
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.